Receptor insulinu sličnog faktora rasta 1 je protein koji je prisutan na površini ljudskih ćelija. On je transmembranskireceptor koji se aktivira IGF-1hormonom (insulinu sličan faktor rasta 1) i srodnim hormonom IGF-2. On pripada velikoj klasi tirozinsko kinaznih receptora . Ovaj receptor posreduje dejstvo IGF-1, koji je polipeptidni proteinski hormon sličan insulinu. IGF-1 utiče na razviće i nastavlja da vrši anaboličko dejstvo kod odraslih. On može da indukuje hipertroifju skeletalnih mišića i drugih ciljnih tkiva. Miševi bez IGF-1 receptora umiru u kasnijem periodu razvića, i manifestuju dramatičnu redukcu telesne mase, što potvrđuje jak uticaj ovog receptora. Miševi sa samo jednom funkcionalnom kopijom IGF1R su normalni, ali ispoljavaju ~15% umanjenje telesne mase.
Postoji evidencija da je IGF1R negativno regulisan dejstvom mikroRNKmiR-7.[17]
References
↑Dey, B R; Furlanetto R W, Nissley P (November 2000). „Suppressor of cytokine signaling (SOCS)-3 protein interacts with the insulin-like growth factor-I receptor”. Biochem. Biophys. Res. Commun. (UNITED STATES) 278 (1): 38–43. DOI:10.1006/bbrc.2000.3762. ISSN0006-291X. PMID11071852.
↑ 3,03,1Seely, B L; Reichart D R, Staubs P A, Jhun B H, Hsu D, Maegawa H, Milarski K L, Saltiel A R, Olefsky J M (August 1995). „Localization of the insulin-like growth factor I receptor binding sites for the SH2 domain proteins p85, Syp, and GTPase activating protein”. J. Biol. Chem. (UNITED STATES) 270 (32): 19151–7. DOI:10.1074/jbc.270.32.19151. ISSN0021-9258. PMID7642582.
↑Dey, B R; Spence S L, Nissley P, Furlanetto R W (September 1998). „Interaction of human suppressor of cytokine signaling (SOCS)-2 with the insulin-like growth factor-I receptor”. J. Biol. Chem. (UNITED STATES) 273 (37): 24095–101. DOI:10.1074/jbc.273.37.24095. ISSN0021-9258. PMID9727029.
↑ 6,06,16,2Dey, B R; Frick K, Lopaczynski W, Nissley S P, Furlanetto R W (June 1996). „Evidence for the direct interaction of the insulin-like growth factor I receptor with IRS-1, Shc, and Grb10”. Mol. Endocrinol. (UNITED STATES) 10 (6): 631–41. DOI:10.1210/me.10.6.631. ISSN0888-8809. PMID8776723.
↑He, W; Rose D W, Olefsky J M, Gustafson T A (March 1998). „Grb10 interacts differentially with the insulin receptor, insulin-like growth factor I receptor, and epidermal growth factor receptor via the Grb10 Src homology 2 (SH2) domain and a second novel domain located between the pleckstrin homology and SH2 domains”. J. Biol. Chem. (UNITED STATES) 273 (12): 6860–7. DOI:10.1074/jbc.273.12.6860. ISSN0021-9258. PMID9506989.
↑Morrione, A; Valentinis B, Li S, Ooi J Y, Margolis B, Baserga R (July 1996). „Grb10: A new substrate of the insulin-like growth factor I receptor”. Cancer Res. (UNITED STATES) 56 (14): 3165–7. ISSN0008-5472. PMID8764099.
↑Mothe, I; Delahaye L, Filloux C, Pons S, White M F, Van Obberghen E (December 1997). „Interaction of wild type and dominant-negative p55PIK regulatory subunit of phosphatidylinositol 3-kinase with insulin-like growth factor-1 signaling proteins”. Mol. Endocrinol. (UNITED STATES) 11 (13): 1911–23. DOI:10.1210/me.11.13.1911. ISSN0888-8809. PMID9415396.
↑Arbet-Engels, C; Tartare-Deckert S, Eckhart W (February 1999). „C-terminal Src kinase associates with ligand-stimulated insulin-like growth factor-I receptor”. J. Biol. Chem. (UNITED STATES) 274 (9): 5422–8. DOI:10.1074/jbc.274.9.5422. ISSN0021-9258. PMID10026153.
↑Rotem-Yehudar, R; Galperin E, Horowitz M (August 2001). „Association of insulin-like growth factor 1 receptor with EHD1 and SNAP29”. J. Biol. Chem. (United States) 276 (35): 33054–60. DOI:10.1074/jbc.M009913200. ISSN0021-9258. PMID11423532.
↑ 12,012,112,2Sehat, Bita; Andersson Sandra, Girnita Leonard, Larsson Olle (July 2008). „Identification of c-Cbl as a new ligase for insulin-like growth factor-I receptor with distinct roles from Mdm2 in receptor ubiquitination and endocytosis”. Cancer Res. (United States) 68 (14): 5669–77. DOI:10.1158/0008-5472.CAN-07-6364. PMID18632619.
↑ 13,013,1Tartare-Deckert, S; Sawka-Verhelle D, Murdaca J, Van Obberghen E (October 1995). „Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system”. J. Biol. Chem. (UNITED STATES) 270 (40): 23456–60. DOI:10.1074/jbc.270.40.23456. ISSN0021-9258. PMID7559507.
↑Craparo, A; Freund R, Gustafson T A (April 1997). „14-3-3 (epsilon) interacts with the insulin-like growth factor I receptor and insulin receptor substrate I in a phosphoserine-dependent manner”. J. Biol. Chem. (UNITED STATES) 272 (17): 11663–9. DOI:10.1074/jbc.272.17.11663. ISSN0021-9258. PMID9111084.
↑Santen, R J; Song R X, Zhang Z, Kumar R, Jeng M-H, Masamura A, Lawrence J, Berstein L, Yue W (July 2005). „Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity”. Endocr. Relat. Cancer. 12 (England) Suppl 1 (Supplement_1): S61–73. DOI:10.1677/erc.1.01018. ISSN1351-0088. PMID16113100.
Gross JM, Yee D (2004). „The type-1 insulin-like growth factor receptor tyrosine kinase and breast cancer: biology and therapeutic relevance.”. Cancer Metastasis Rev.22 (4): 327–36. DOI:10.1023/A:1023720928680. PMID12884909.
Adams TE, McKern NM, Ward CW (2005). „Signalling by the type 1 insulin-like growth factor receptor: interplay with the epidermal growth factor receptor.”. Growth Factors22 (2): 89–95. DOI:10.1080/08977190410001700998. PMID15253384.
Surmacz E, Bartucci M (2005). „Role of estrogen receptor alpha in modulating IGF-I receptor signaling and function in breast cancer.”. J. Exp. Clin. Cancer Res.23 (3): 385–94. PMID15595626.
Sarfstein R, Maor S, Reizner N, et al. (2006). „Transcriptional regulation of the insulin-like growth factor-I receptor gene in breast cancer.”. Mol. Cell. Endocrinol.252 (1-2): 241–6. DOI:10.1016/j.mce.2006.03.018. PMID16647191.